5 Contents

6-7 NEWS
Lilly to acquire Kelonia in $7bn deal; Boehringer and Immunitas in global licensing agreement

8-9 NEWS
EC approves RSV antibody for infants; UCB highlights impact of epilepsy on daily life

11-12 DERMATOLOGY NEWS
J&J's Icotyde approved by US FDA; Almirall and Shanghai Huaota agree on deal

12 DARWIN’S MEDICINE
Novo Nordisk and the Panda’s Thumb

13 PARTNERSHIP HEALTH
Arts-based therapies can improve quality of life

14 INTEGRATED INSIGHTS
Thinking more clearly about AI implementation

15 WHERE TO PLAY IN ONCOLOGY
Changing the quality of the discussion

16-17 MEN’S HEALTH – THE GAP BETWEEN AWARENESS AND ACTION where lives are lost
In England, more than one in three men will not live to see their 75th birthday. Despite years of growing awareness campaigns, government strategies and public conversation, that is still the reality today rather than a statistic from decades past

18-20 PHESI REPORT – THE NEXT FRONTIER IN CLINICAL TRIALS
Navigating multi-disease research with GLP-1s – as these therapies redefine the treatment landscape for obesity, they are also promising candidates to influence a wide range of disease pathways

22-23 RECOGNISING OBESITY AS A CHRONIC DISEASE
Obesity care in the UK can’t improve until it is recognised as a disease. Even though the WHO classified obesity as a chronic disease over twenty years ago, UK policy has yet to follow

24-25 SUPPORTING BRAIN HEALTH IN EUROPE THROUGH INNOVATION
To succeed, Europe needs to move beyond a ‘health budget’ mindset – which views healthcare as a fiscal cost – towards a model that treats the life sciences as a fundamental investment in our long-term prosperity

28-29 MAKING HEADWAY TOWARDS GREATER PATIENT ACCESS THROUGH FAVOURABLE TRADE WINDS AND MARKET DEALS
Regulatory changes and tariffs have created a positive climate for investment, innovation and, critically, patient access to therapies, and the incentive to launch innovative medicines and supercharge the mechanics of getting them to patients has been given a rare boost

33-35 HEALTHCARE COMMS–CURRENT TOPICS
Exploring important topics affecting the healthcare comms industry today, from human-centricity in trial design to how GenAI can strengthen engagement with HCPs

APRIL 2026